Sign in
Taking people in South KoreaPhase 3

New treatments tested in adults with colorectal cancer that has spread after earlier treatment

Compares precemtabart tocentecan with or without bevacizumab against standard treatment in colorectal cancer.

Key facts

Who runs it
EMD Serono Research & Development Institute, Inc.
Where
Daegu, Goyang-si, Seongnam-si, and Seoul, South KoreaSee the 9 sitesAlso in 18 other countries, 121 sites
Trial code
Registry title
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Status
Recruiting
Phase
Phase 3
People taking part
1,020 people, planned
Started
6 May 2026
Expected to end
16 Oct 2029
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Precemtabart tocentecan
  • Bevacizumab
  • Trifluridine/Tipiracil (FTD-TPI)
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with colorectal cancer that has spread, who have already had treatment, and whose cancer stopped responding or who could not tolerate it.

Age
18 years or older
Sex
All sexes can join
Disease stage
Colorectal cancer that has spread (metastatic), confirmed by tissue examination
Earlier treatment
Must have had standard drug treatments and no more than 2 earlier treatment regimens for the spread disease, and the cancer got worse, stopped responding, or the treatments were not tolerated. The summary names irinotecan, oxaliplatin, a fluoropyrimidine and bevacizumab as earlier treatments.

Main reasons for not taking part

  • Side effects from earlier treatments not yet recovered to below Grade 1
  • Another cancer within the last 3 years
  • Known brain metastases
  • Abdominal fistula, bowel perforation or abscess in the abdomen within the last 6 months
  • Bowel obstruction, ileus above Grade 1, chronic inflammatory bowel disease, or other gut disorders that may affect how tablets are absorbed

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Participants with documented histopathological diagnosis of metastatic colorectal cancer, who were intolerant to, or whose disease was refractory to, or progressed after standard systemic therapies and no more than 2 previous systemic treatment regimens in the metastatic setting
  • Participants must have received and progressed on no more than 2 previous systemic treatment regimens in the metastatic setting
  • Eastern Cooperative Oncology Group (ECOG) performance status less than equal to 1
  • Participants must be able to swallow oral tablets, and to comply with the study requirements for all scheduled evaluations
  • Other protocol defined inclusion criteria may apply

Who cannot take part

  • If Adverse Events related to previous therapies have not recovered to less than Grade 1 by National Cancer Institute - Common Terminology Criteria for Adverse Events version 6.0
  • Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months prior to randomization
  • Participant has a history of additional malignancy within 3 years before randomization
  • Participants with ileus of more than Grade 1, or chronic inflammatory bowel disease (example ulcerative colitis, Crohn's disease) and/or bowel obstruction, or participants with chronic gastrointestinal disorders that, in the Investigator's opinion, might significantly interfere with proper absorption of the study treatments
  • Participants with known brain metastases
  • Other protocol defined exclusion criteria may apply

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • How many different drug treatment plans (such as chemotherapy) have you had for cancer that has spread?
  • Have you had another type of cancer in the past 3 years?

Where in South Korea

Also in 18 other countries, 121 sites

  • Kyungpook National University Chilgok HospitalDaegu, South KoreaContact: Communication CenterTaking people
  • National Cancer CenterGoyang-si, South KoreaContact: Communication CenterTaking people
  • Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Communication CenterTaking people
  • Asan Medical CenterSeoul, South KoreaContact: Communication CenterTaking people
  • Korea University Guro HospitalSeoul, South KoreaContact: Communication CenterTaking people
  • Samsung Medical CenterSeoul, South KoreaContact: Communication CenterTaking people
  • Seoul National University HospitalSeoul, South KoreaContact: Communication CenterTaking people
  • Severance Hospital, Yonsei University Health System - Division of Infectious DiseasesSeoul, South KoreaContact: Communication CenterTaking people
  • The Catholic University of Korea, Seoul St. MaryâSeoul, South KoreaContact: Communication CenterTaking people

About the trial

What the trial wants to find out

This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluridine/tipiracil (FTD-TPI) plus bevacizumab.

The 3 groups in the trial

  • Arm 1: Precemtabart tocentecan (Precem-TcT) MonotherapyTreatment being tested

    Treatment: Precemtabart tocentecan

  • Arm 2: Precem-TcT plus BevacizumabTreatment being tested

    Treatment: Precemtabart tocentecan and Bevacizumab

  • Arm 3: Trifluridine/Tipiracil (FTD-TPI) plus BevacizumabExisting treatment, for comparison

    Treatment: Bevacizumab and Trifluridine/Tipiracil (FTD-TPI)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Plain-language title
New treatments tested in adults with colorectal cancer that has spread after earlier treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07549412, who can take part
Record updated
5 November 2026